Insider Trading April 6, 2026

Arteris CFO Sells Shares to Cover RSU Taxes After Strong Quarter; Stock Seen as Overvalued by InvestingPro

Nicholas B. Hawkins sold 5,870 shares on April 2, 2026; Arteris outperformed Q4 2025 revenue and EPS estimates

By Hana Yamamoto AIP
Arteris CFO Sells Shares to Cover RSU Taxes After Strong Quarter; Stock Seen as Overvalued by InvestingPro
AIP

Arteris, Inc. CFO Nicholas B. Hawkins disposed of 5,870 shares on April 2, 2026, in multiple transactions disclosed on a Form 4, raising $85,969. The sales were reported as tax-covering actions tied to the vesting of restricted stock units. Arteris recently posted better-than-expected fourth-quarter 2025 results, while InvestingPro flags the stock as overvalued at current levels.

Key Points

  • Arteris CFO Nicholas B. Hawkins sold 5,870 shares on April 2, 2026, in multiple transactions at $17.6528 per share, totaling $85,969.
  • The sales were disclosed on a Form 4 and were conducted to cover tax obligations arising from the release of restricted stock units under Arteris' equity incentive plans.
  • Arteris beat fourth-quarter 2025 revenue and EPS expectations—reporting $20.1 million in revenue versus an $18.55 million projection and EPS of -$0.05 versus an anticipated -$0.07—followed by a notable aftermarket rise; InvestingPro considers AIP overvalued.

Nicholas B. Hawkins, who serves as Vice President and Chief Financial Officer of Arteris, Inc. (NASDAQ: AIP), executed a series of sales of common stock on April 2, 2026. According to a Form 4 filing with the Securities and Exchange Commission, Hawkins sold 5,870 shares at a per-share price of $17.6528, generating proceeds of $85,969.

The filing indicates multiple transactions comprised the disposition. After the sales were completed, Hawkins retained direct ownership of 118,614 shares of Arteris stock.

Company disclosure accompanying the filing states that the sales were made to satisfy tax obligations associated with the release of restricted stock units, in accordance with Arteris' equity incentive plans.


Market context and valuation note

Arteris shares have appreciated sharply over the past year, rising 205% in that period. The stock was trading at $18.24 at the time of the report, and the company carried a market capitalization of $827.5 million. Separately, InvestingPro analysis cited in the filing indicates that AIP appears overvalued at current levels.


Recent financial results

In related corporate developments, Arteris reported fourth-quarter 2025 financial results that beat expectations on both top and bottom lines. Revenue for the quarter was reported at $20.1 million, ahead of a projected $18.55 million. Earnings per share were -$0.05, outperforming an anticipated -$0.07. Following the earnings release, Arteris shares experienced a notable uptick in aftermarket trading, reflecting investor response to the stronger-than-expected figures. The company outperformed analyst forecasts for the quarter, according to the disclosure.


What the filings and results show

  • The Form 4 documents the insider sale and remaining direct ownership of Hawkins.
  • Arteris' quarter exceeded revenue and EPS expectations, and shares rose in aftermarket activity.
  • Independent valuation commentary from InvestingPro characterizes the stock as appearing overvalued at current market levels.

These items together provide a snapshot of recent insider activity, company performance for Q4 2025, and an outside valuation opinion. The filing attributes the insider sale to tax obligations tied to the vesting of equity awards, rather than to an articulated change in view on the company.

Risks

  • Valuation risk: InvestingPro analysis states AIP appears overvalued at current trading levels, which could affect investor expectations in the equities market.
  • Liquidity events from equity compensation: Sales to cover tax obligations tied to restricted stock unit releases can put incremental supply into the market, introducing near-term trading pressure in the stock.
  • Market reaction uncertainty: Despite the quarter beating revenue and EPS estimates and prompting aftermarket gains, future trading responses remain uncertain and tied to ongoing performance and valuation perceptions.

More from Insider Trading

Penumbra Director Executes $32,822 Stock Sale Amid Deal and Upbeat Quarterly Results Apr 6, 2026 Power Integrations VP Sells 313 Shares to Cover Tax Bill; Stock Up 45% YTD Apr 6, 2026 Lipocine Director Purchases 123,000 Shares Amid Mixed Clinical News Apr 6, 2026 Kinder Morgan Vice President Disposes of $203K in Class P Shares Apr 6, 2026 RA Capital Disposes $14.5M of Vor Biopharma Stock Across Early April Trades Apr 6, 2026